PL3227313T3 - Polipeptydy zawierające zmodyfikowaną sekwencję aminokwasową bakteriofaga g3p pozbawioną sygnału glikozylacji - Google Patents
Polipeptydy zawierające zmodyfikowaną sekwencję aminokwasową bakteriofaga g3p pozbawioną sygnału glikozylacjiInfo
- Publication number
- PL3227313T3 PL3227313T3 PL15831011T PL15831011T PL3227313T3 PL 3227313 T3 PL3227313 T3 PL 3227313T3 PL 15831011 T PL15831011 T PL 15831011T PL 15831011 T PL15831011 T PL 15831011T PL 3227313 T3 PL3227313 T3 PL 3227313T3
- Authority
- PL
- Poland
- Prior art keywords
- polypeptides
- amino acid
- acid sequence
- sequence lacking
- modified bacteriophage
- Prior art date
Links
- 230000013595 glycosylation Effects 0.000 title 1
- 238000006206 glycosylation reaction Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 241001515965 unidentified phage Species 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1716—Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087052P | 2014-12-03 | 2014-12-03 | |
| EP15831011.0A EP3227313B1 (en) | 2014-12-03 | 2015-12-02 | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal |
| PCT/US2015/063476 WO2016090022A1 (en) | 2014-12-03 | 2015-12-02 | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3227313T3 true PL3227313T3 (pl) | 2022-05-09 |
Family
ID=55273507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15831011T PL3227313T3 (pl) | 2014-12-03 | 2015-12-02 | Polipeptydy zawierające zmodyfikowaną sekwencję aminokwasową bakteriofaga g3p pozbawioną sygnału glikozylacji |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10722551B2 (pl) |
| EP (1) | EP3227313B1 (pl) |
| JP (2) | JP6730988B2 (pl) |
| KR (1) | KR20170085132A (pl) |
| CN (1) | CN107250154A (pl) |
| AR (1) | AR102890A1 (pl) |
| AU (1) | AU2015358504A1 (pl) |
| BR (1) | BR112017011530A2 (pl) |
| CA (1) | CA2969128A1 (pl) |
| DK (1) | DK3227313T3 (pl) |
| EA (1) | EA201791212A1 (pl) |
| ES (1) | ES2910017T3 (pl) |
| IL (1) | IL252426A0 (pl) |
| MX (1) | MX2017007059A (pl) |
| PH (1) | PH12017501004A1 (pl) |
| PL (1) | PL3227313T3 (pl) |
| PT (1) | PT3227313T (pl) |
| SG (1) | SG11201704427YA (pl) |
| TW (1) | TW201632542A (pl) |
| WO (1) | WO2016090022A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6220344B2 (ja) | 2011-11-29 | 2017-10-25 | プロクララ バイオサイエンシーズ， インコーポレイテッド | アミロイド結合剤としてのバクテリオファージのｐ３の使用 |
| DK2906235T3 (en) | 2012-10-02 | 2017-09-25 | Proclara Biosciences Inc | USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS |
| WO2014193935A1 (en) | 2013-05-28 | 2014-12-04 | Neurophage Pharmaceuticals, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
| JP6730988B2 (ja) | 2014-12-03 | 2020-07-29 | プロクララ バイオサイエンシーズ， インコーポレイテッド | グリコシル化シグナルを欠く改変バクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド |
| US11692017B2 (en) * | 2018-06-15 | 2023-07-04 | Amyl Therapeutics Srl | General amyloid interaction motif (GAIM) |
| JP2025539186A (ja) | 2022-12-02 | 2025-12-03 | アルツェオン・インコーポレーテッド | トラミプロセートを用いて神経変性障害を治療する方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
| EP1132471A3 (de) | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| CA2106079C (en) | 1991-03-15 | 2000-04-25 | Robert C. Thompson | Pegylation of polypeptides |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| ES2252732T3 (es) | 1992-05-26 | 2006-05-16 | Immunex Corporation | Nueva citoquina que une cd30. |
| GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
| DE69934967T2 (de) | 1998-12-08 | 2007-12-06 | Biovation Ltd. | Verfahren zur verminderung der immunogenität von proteinen |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
| KR20040074587A (ko) | 2001-02-19 | 2004-08-25 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 인공 단백질 |
| HUP0303429A3 (en) | 2001-03-08 | 2005-12-28 | Merck Patent Gmbh | Modified granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity |
| DE10238846A1 (de) | 2002-08-20 | 2004-03-04 | Nemod Immuntherapie Ag | Aktive Fusionsproteine und Verfahren zu ihrer Herstellung |
| JP5096169B2 (ja) | 2005-02-01 | 2012-12-12 | ラモット・アット・テルアビブ・ユニバーシティ | アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法 |
| US20090304726A1 (en) | 2006-02-15 | 2009-12-10 | Ramot At Tel Aviv University Ltd. | Viral display vehicles for treating multiple sclerosis |
| MX2008010612A (es) | 2006-02-15 | 2009-03-20 | Ramot At Tel Aviv University | Bacteriofago filamentoso que exhibe proteina a como aglutinante de anticuerpos e inmunocomplejos para el suministro hacia el cerebro. |
| WO2007109733A2 (en) | 2006-03-21 | 2007-09-27 | The Johns Hopkins University | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis |
| WO2007114139A1 (ja) | 2006-04-06 | 2007-10-11 | Fumiaki Uchiyama | 新規繊維状ファージによるファージディスプレイ |
| US20090324554A1 (en) | 2006-07-21 | 2009-12-31 | Ramot At Tel Aviv University Ltd. | Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar or aggregates |
| SG10201502661SA (en) | 2006-10-11 | 2015-05-28 | Antitope Ltd | T cell epitope databases |
| EP2303315A1 (en) | 2008-05-22 | 2011-04-06 | Ramot at Tel Aviv University Ltd. | Method for treating disease characterized by plaque |
| EP2478911A1 (en) | 2008-11-24 | 2012-07-25 | Ramot at Tel Aviv University Ltd. | Method for treating Parkinson's disease using filamentous bacteriophage |
| WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| JP2014509514A (ja) | 2011-03-11 | 2014-04-21 | ラモット アット テルアヴィブ ユニヴァーシティ リミテッド | 神経変性タウオパシーを治療するための方法 |
| JP6220344B2 (ja) | 2011-11-29 | 2017-10-25 | プロクララ バイオサイエンシーズ， インコーポレイテッド | アミロイド結合剤としてのバクテリオファージのｐ３の使用 |
| DK2906235T3 (en) | 2012-10-02 | 2017-09-25 | Proclara Biosciences Inc | USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS |
| WO2014193935A1 (en) * | 2013-05-28 | 2014-12-04 | Neurophage Pharmaceuticals, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
| JP6730988B2 (ja) | 2014-12-03 | 2020-07-29 | プロクララ バイオサイエンシーズ， インコーポレイテッド | グリコシル化シグナルを欠く改変バクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド |
-
2015
- 2015-12-02 JP JP2017529043A patent/JP6730988B2/ja active Active
- 2015-12-02 KR KR1020177017763A patent/KR20170085132A/ko not_active Withdrawn
- 2015-12-02 BR BR112017011530A patent/BR112017011530A2/pt not_active Application Discontinuation
- 2015-12-02 AU AU2015358504A patent/AU2015358504A1/en not_active Abandoned
- 2015-12-02 CA CA2969128A patent/CA2969128A1/en not_active Abandoned
- 2015-12-02 WO PCT/US2015/063476 patent/WO2016090022A1/en not_active Ceased
- 2015-12-02 SG SG11201704427YA patent/SG11201704427YA/en unknown
- 2015-12-02 TW TW104140347A patent/TW201632542A/zh unknown
- 2015-12-02 MX MX2017007059A patent/MX2017007059A/es unknown
- 2015-12-02 PL PL15831011T patent/PL3227313T3/pl unknown
- 2015-12-02 US US15/532,820 patent/US10722551B2/en active Active
- 2015-12-02 ES ES15831011T patent/ES2910017T3/es active Active
- 2015-12-02 PT PT158310110T patent/PT3227313T/pt unknown
- 2015-12-02 CN CN201580065696.9A patent/CN107250154A/zh active Pending
- 2015-12-02 EA EA201791212A patent/EA201791212A1/ru unknown
- 2015-12-02 EP EP15831011.0A patent/EP3227313B1/en active Active
- 2015-12-02 DK DK15831011.0T patent/DK3227313T3/da active
- 2015-12-03 AR ARP150103956A patent/AR102890A1/es unknown
-
2017
- 2017-05-22 IL IL252426A patent/IL252426A0/en unknown
- 2017-05-31 PH PH12017501004A patent/PH12017501004A1/en unknown
-
2020
- 2020-02-19 JP JP2020026300A patent/JP2020073610A/ja not_active Withdrawn
- 2020-06-18 US US16/905,128 patent/US11723951B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2910017T3 (es) | 2022-05-11 |
| WO2016090022A8 (en) | 2017-06-22 |
| PT3227313T (pt) | 2022-04-12 |
| MX2017007059A (es) | 2018-05-02 |
| EP3227313B1 (en) | 2022-02-09 |
| WO2016090022A1 (en) | 2016-06-09 |
| US20180207231A1 (en) | 2018-07-26 |
| JP2017538407A (ja) | 2017-12-28 |
| TW201632542A (zh) | 2016-09-16 |
| US20210015895A1 (en) | 2021-01-21 |
| AR102890A1 (es) | 2017-03-29 |
| AU2015358504A1 (en) | 2017-06-29 |
| JP2020073610A (ja) | 2020-05-14 |
| US10722551B2 (en) | 2020-07-28 |
| KR20170085132A (ko) | 2017-07-21 |
| US11723951B2 (en) | 2023-08-15 |
| EP3227313A1 (en) | 2017-10-11 |
| BR112017011530A2 (pt) | 2018-03-13 |
| CN107250154A (zh) | 2017-10-13 |
| SG11201704427YA (en) | 2017-06-29 |
| DK3227313T3 (da) | 2022-04-19 |
| WO2016090022A9 (en) | 2016-08-25 |
| IL252426A0 (en) | 2017-07-31 |
| EA201791212A1 (ru) | 2018-01-31 |
| CA2969128A1 (en) | 2016-06-09 |
| JP6730988B2 (ja) | 2020-07-29 |
| AU2015358504A8 (en) | 2017-07-13 |
| PH12017501004A1 (en) | 2017-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258041B (en) | A new endolysin polypeptide | |
| ZA201802261B (en) | Polypeptides | |
| IL254965A0 (en) | fusion proteins | |
| IL254577A0 (en) | polypeptides | |
| EP3371349A4 (en) | Conditionally active polypeptides | |
| IL252426A0 (en) | Polypeptides containing a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal | |
| ZA201704366B (en) | Il-17a-binding polypeptides | |
| SG11201509647WA (en) | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity | |
| SG11201706882VA (en) | Polypeptides | |
| IL248276B (en) | Carbohydrate binding proteins | |
| GB201600512D0 (en) | Recombinant protein production | |
| GB201520545D0 (en) | Peptides | |
| GB201520562D0 (en) | Peptides | |
| GB201708277D0 (en) | A Recombinant protein | |
| GB201520558D0 (en) | Peptides | |
| HK1249520A1 (en) | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal | |
| HK40081641B (zh) | 条件活性多肽 | |
| GB201622073D0 (en) | Improved recombinant protein production system | |
| GB201617799D0 (en) | Fusion polypeptide | |
| GB201503789D0 (en) | Fusion polypeptide | |
| GB201520537D0 (en) | Peptides | |
| GB201520534D0 (en) | Peptides | |
| GB201520576D0 (en) | Peptides | |
| GB201520585D0 (en) | Peptides | |
| GB201520599D0 (en) | Peptides |